Biocon Limited — Credit Ratings, 26-11-2024: Credit Rating

Biocon has released its consolidated financial results, reporting total revenue of ₹7,023 crore, reflecting a 2% year-over-year growth. This growth can be attributed primarily to a notable 15% increase in the biosimilars segment, driven by heightened demand in the US and steady expansion in Europe and emerging markets. Conversely, the generics business faced challenges with a 7% decline in revenue due to pricing pressures and a planned facility shutdown.

The reported net profit stands at ₹1,298 crore, resulting in an Earnings Per Share (EPS) of approximately 8.85, up from 5.8 in the previous year. However, margins have contracted with EBITDA margins declining to 19.0%, down from 22.2% the prior year. Increased operational costs, mainly from R&D and integration costs, have impacted profitability.

Operational costs have risen, reflecting a shift in business focus and expansion, which is indicative of the company's ongoing efforts in the competitive biopharma space. Despite the increased expenditures, Biocon's balance sheet remains robust, with healthy cash flow generation due to substantial completion of acquisitions.

Strategically, Biocon's focus remains on leveraging its strong biosimilars pipeline and improving operational efficiency. The outlook suggests potential for recovery in the generics segment and continued growth in biosimilars, supported by upcoming product launches. Given the current financial performance and operational prospects, investors may consider holding their positions, while monitoring future growth in key product sectors.

Biocon has had its credit ratings reaffirmed at CRISIL AA+/Stable for long-term and CRISIL A1+ for short-term facilities. The reaffirmation highlights Biocon’s strong market position, diverse revenue streams, and healthy product pipeline, despite facing challenges like regulatory scrutiny and competition in the sector. This stable rating reflects the company's ongoing efforts to reduce leverage, manage operational costs, and support sustainable growth through strategic R&D investments.